Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
The purpose of this study is to investigate whether Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment as 1st line treatment in he advanced gastric cancer is effective and safe.
Advanced Gastric Cancer
DRUG: Paclitaxel|DRUG: capecitabine|DRUG: capecitabine|DRUG: cisplatin
Progression free survival, 3 year
Tumor response rate, 1 year|Disease control rate, 1 year|Overall survival, 5 year|adverse evens, 5 year
The purpose of this study is to investigate whether Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment as 1st line treatment in he advanced gastric cancer is effective and safe.